BridgeBio Pharma (BBIO) Current Assets (2018 - 2026)

BridgeBio Pharma has disclosed Current Assets across 9 years of filings, most recently posting $1.2 billion for Q1 2026.

• Current Assets for Q1 2026 came in at $1.2 billion, up 78.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 78.56% YoY), and the FY2025 annual result was $797.7 million, up 10.69% from the prior year.
• Current Assets came in at $1.2 billion for Q1 2026 at BridgeBio Pharma, up from $797.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.2 billion in Q1 2026 to a low of $432.9 million in Q2 2023.
• The 5-year median for Current Assets is $695.2 million (2025), against an average of $693.0 million.
• Across the five-year window, Current Assets slumped 43.87% in 2023 and surged 88.8% in 2025, its largest moves.
• BridgeBio Pharma's Current Assets stood at $548.9 million in 2022, then fell by 12.98% to $477.6 million in 2023, then soared by 50.9% to $720.7 million in 2024, then increased by 10.69% to $797.7 million in 2025, then soared by 55.6% to $1.2 billion in 2026.
• The last three Current Assets figures came in at $1.2 billion (Q1 2026), $797.7 million (Q4 2025), and $839.4 million (Q3 2025), per Business Quant data.